<DOC>
	<DOC>NCT00251914</DOC>
	<brief_summary>The aim is to evaluate if the resolution of upper abdominal symptoms (pain or burning) during an acid suppressive test trial of esomprazole given daily for 7 days predicts symptoms resolution at the end of a subsequent treatment period of 7 weeks.</brief_summary>
	<brief_title>Nexium Dyspepsia/AST</brief_title>
	<detailed_description />
	<mesh_term>Signs and Symptoms</mesh_term>
	<mesh_term>Dyspepsia</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<mesh_term>Signs and Symptoms, Digestive</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>At least 3 months of symptoms of pain or burning centered in the upper abdomen prior to enrollment. Both Helicobacter pylori positive and negative patients eligible (Helicobacter pylori is a bacterial infection of the stomach) Presence of clinical significant abnormal findings at the endoscopy (examination of esophagus and stomach) prior to enrollment. Patients with symptoms of other gastrointestinal diseases, such as Gastroesophageal Reflux Disease (GERD), Irritable Bowel Syndrome (IBS) or Inflammatory Bowel Disease (IBD). Helicobacter pylori eradication treatment during the last 12 months prior to enrollment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>